| abstract |
This application discloses compounds according to formula I:n□ where all variables are as defined herein, and such compounds inhibit Btk. The compounds disclosed herein are useful for modulating the activity of Btk and treating diseases associated with excessive Btk activity. These compounds are useful for the treatment of carcinogenic, autoimmune and inflammatory diseases caused by abnormal B cell activation. The present application also discloses compositions comprising a compound of formula I and at least one carrier, diluent or excipient. |